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Lactose malabsorption and intolerance:
pathogenesis, diagnosis and treatment
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Abstract
Lactose malabsorption is a common condition caused by reduced expression or activity of lactase in the small intestine. In
such patients, lactose intolerance is characterized by abdominal symptoms (e.g. nausea, bloating, and pain) after ingestion
of dairy products. The genetic basis of lactose malabsorption is established and several tests for this condition are available,
including genetic, endoscopic, and H2-breath tests. In contrast, lactose intolerance is less well understood. Recent studies
show that the risk of symptoms after lactose ingestion depends on the dose of lactose, lactase expression, intestinal flora,
and sensitivity of the gastrointestinal tract. Lactose intolerance has recently been defined as symptoms developing after
ingestion of lactose which do not develop after placebo challenge in a person with lactose maldigestion. Such blinded
testing might be especially important in those with functional gastrointestinal diseases in whom self-reported lactose
intolerance is common. However, placebo-controlled testing is not part of current clinical practice. Updated protocols
and high-quality outcome studies are needed. Treatment options of lactose intolerance include lactose-reduced diet and
enzyme replacement. Documenting the response to multiple doses can guide rational dietary management; however, the
clinical utility of this strategy has not been tested. This review summarizes the genetic basis, diagnosis, and treatment of
lactose malabsorption and intolerance.
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Digestion of lactose
Lactose malabsorption refers to ineﬃcient digestion
of lactose due to reduced expression or impaired
activity of the enzyme lactase (Box 1). After inges-
tion, lactose passes into the small intestine where it
comes into contact with lactase at the intestinal brush
border where it is hydrolysed into the monosacchar-
ides glucose and galactose, which can be readily
absorbed.1
Lactose is the main source of sugar from milk and
milk products from all mammals except the sea lion.
Inadequate lactase activity allows lactose to reach the
large intestine. There, the gut ﬂora provides a salvage
pathway for lactose digestion by cleaving lactose into
short-chain fatty acids (SCFA) and gas, mainly hydro-
gen (H2), carbon dioxide (CO2), and methane (CH4).
Non-digested lactose can cause osmotic diarrhoea;
products of its bacterial digestion can lead to secretory
diarrhoea and gas distending the intestines, events that
are likely to lead to clinical symptoms.2
Causes of lactase deficiency
The most frequent cause of lactose malabsorption is
lactase non-persistence, a common condition in which
lactase expression decreases during infancy. In contrast,
congenital lactase deﬁciency due to complete lack of the
enzyme is a rare condition that presents with severe
symptoms in newborns. In addition, lactase
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malabsorption may be secondary to acquired condi-
tions including small bowel bacterial overgrowth, infec-
tious enteritis (i.e. giardiasis), or mucosal damage due
to coeliac disease, inﬂammatory bowel disease, drugs,
gastrointestinal surgery, short bowel syndrome, or radi-
ation enteritis, conditions that lead to either reduction
of absorptive capacity or downregulation of lactase
expression in the small intestine.
Genetics of lactase non-persistence
Lactase activity changes during development. In most
humans, lactase activity reaches a maximum in late
pregnancy but declines after 2–3 years of age and
reaches a stable low level at age 5–10, a process which
might help weaning. However, a proportion of the
human population, especially Caucasians from
Northern Europe or northern European descent,
retain high lactase levels during adulthood (lactase per-
sistence). Both, lactase persistence and non-persistence
(leading to lactose malabsorption) are thus normal
human phenotypes.3
Prevalence of lactase persistence is high in most
regions in Scandinavia, the British islands, and
Germany (80–95%); however, this condition is
observed in only 20–40% of Indian adults, 30% of
Mexicans, 30% of African Americans, and <10% of
adults in Southeast Asia4,5 (Figure 1). Lactase persist-
ence is thought to be related to the development of
farming during the last 10,000 years. The genetic poly-
morphism responsible for most cases of lactase persist-
ence in Caucasian individuals is the 13910C/T variant
(thereby, T at position 13910 upstream of the lactase
gene within a putative regulatory DNA-region causes
persistence; C leads to non-persistence).6 In contrast, in
African tribes that herd cattle in Sudan, Kenya, and
Tanzania), lactase persistence is mediated by the
14010*G, 13915*G or 13907*C polymorphism,3,7
and in Saudi Arabia by the 13915*G polymorphism.8
Thus, lactase persistence developed several times inde-
pendently in human evolution in diﬀerent areas of the
world (for review, see Ingram et al.3).
Statistical calculations of genetic data estimated that
selection for lactase persistence commenced relatively
recently, during the last 10,000 years.3,9,10 Lactase per-
sistence was beneﬁcial for our ancestors by providing a
clean source of ﬂuid and a source of protein, fat, and
carbohydrates.3 Lactase persistence generated a select-
ive advantage of 1.5–19% in each generation.7,9 This
indicates a strong selection pressure comparable to mal-
aria resistance genes (2–5% for G6PD deﬁciency,
5–18% for sickle-cell trait) in various parts of the world.
The exact molecular mechanism for lactase persist-
ence is unknown but factors enhancing gene transcrip-
tion appear to be responsible by binding to a regulatory
region 13,000 to 14,030 base pairs upstream of the lac-
tase gene.3,11–13 In adult patients with homozygous
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Figure 1. Interpolated frequency of the lactose malabsorption phenotype in the Eastern Hemisphere
Dots indicate locations of data collection. In regions with few data points (for instance Australia) this map is less reliable. Figure modified
from Itan et al.5
Box 1. Definition of important concepts
Lactase non-persistence: In a majority of humans, the enzyme
lactase at the jejunal brush border is reduced in activity after
weaning. In some individuals, this reduced activity can cause
symptoms after lactose ingestion.
Lactase persistence: Persistence of a high activity of the enzyme
lactase into adulthood. This phenotype facilitates digestion of
larger of amounts of lactose.
Lactose malabsorption: Inefficient digestion of lactose due to lac-
tase non-persistence or other intestinal pathologies.
Lactose malassimilation: Inefficient absorption of lactose due to
lactose malabsorption.
Lactose intolerance: Gastrointestinal symptoms in an individual
with lactose malabsorption.
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lactase persistence, enzyme levels at the jejunal brush
border are 10-times higher than for patients with homo-
zygous non-persistence, heterozygous individuals show-
ing intermediate levels.14
Definition of lactose intolerance
The lactose-rich diet in Western countries can cause
symptoms in individuals with the lactase non-persis-
tence phenotype. Typical gastrointestinal complaints
are diarrhoea, nausea, bloating, borborygmi, and
abdominal pain. A wide range of systemic problems
have also been associated with lactose malabsorption
including skin disease, rheumatological complaints,
chronic fatigue, and failure to thrive in children,15
although the concept of ‘systemic lactose intolerance’
is still controversial. It is important to realize that lac-
tose malabsorption (lactase non-persistence) is not
equivalent or synonymous to lactose intolerance.
Lactose malabsorption in many cases will not come
to clinical attention. Development of symptoms
depends on several individual factors including diet,
oro-cecal transit time, distribution and fermentation
capacity of gut ﬂora,16 sensitivity towards chemical
and mechanical stimulation of the gut, and psycho-
logical factors.17
A recent NIH conference deﬁned lactose intolerance
as ‘the onset of gastrointestinal symptoms following a
blinded, single-dose challenge of ingested lactose by an
individual with lactose malabsorption, which are not
observed when the person ingests an indistinguishable
placebo’.1 This new concept of lactose intolerance is
provoking because it requires, in addition to evidence
of lactase deﬁciency or lactose malabsorption, the
development of symptoms after a blinded, placebo-con-
trolled lactose challenge, which currently is not clinical
practice.
Testing of lactose malabsorption
Typical symptoms of lactose intolerance are common
among patients in a primary care setting but no con-
sensus exists concerning which patients should be
referred for further testing. In a recent meta-analysis,
no speciﬁc complaint could predict lactose malabsorp-
tion, with sensitivities ranging from 0 to 90% and spe-
ciﬁcities ranging from 18 to 96% for symptoms such as
bloating, diarrhoea, ﬂatulence, and abdominal pain in
individual studies.18 Self-reported milk intolerance was
also of little value, showing sensitivities from 30 to 71%
and speciﬁcities from 25 to 87%.18
Various options exist for diagnosing lactose malab-
sorption (Table 1). Testing of lactase activity in muco-
sal biopsies from the duodenum may be the reference
standard19,20 and has the advantage that endoscopy
and biopsy can also exclude other conditions that
cause secondary lactose malabsorption (e.g. coeliac dis-
ease). Limitations are the patchy expression of lactase21
and the invasiveness of the test. Recently, an open-label
trial in patients with self-reported intolerance of dairy
products (excluding irritable bowel syndrome, IBS)
reported that a commercial lactase assay was able to
predict symptom improvement after implementation of
an lactose-free diet more accurately than an H2-breath
test (98 vs. 81%).22
Genetic tests establish lactase non-persistence in
Caucasian patients and the 13910*T genotype corre-
lated closely (86–95%) with other tests for lactose mal-
absorption in European countries.6,23,24 Since lactose
malabsorption is a recessive condition, a heterozygous
genotype has to be considered a negative test result.
Current testing for the 13910*T genotype is of limited
use in certain African, Arabic, or Asian subpopulations
where lactase persistence may be linked to diﬀerent
polymorphisms, as already discussed. Future genetic
tests will likely cover a range of genetic polymorphisms,
potentially eliminating this limitation. Clearly, genetic
tests will be negative in patients with secondary causes
of lactase deﬁciency. Importantly, no information
about clinical symptoms lactose intolerance is obtained
during testing.
Lactose digestion can also be assessed by the lactose
tolerance test25 and the H2-breath test.
2,19,20 Both tests
include an oral challenge with a standard dose of lac-
tose (usually 20–50 g, corresponding to the lactose con-
tent of approximately 400–1000ml cow milk). While
the lactose tolerance test relies on an increase in
blood glucose, the H2-breath test detects H2 produced
by intestinal bacteria in expiratory air. The lactose tol-
erance test can be confounded by ﬂuctuations of post-
prandial blood sugar in patients with impaired glucose
tolerance or diabetes. The H2-breath test can be false-
positive in the presence of small intestinal bacterial
overgrowth.26 False-negative results for the H2-breath
are observed for ‘H2-non-producers’, the 2–43% of
individuals (<10% in most studies) in whom the
bowel ﬂora does not produce hydrogen.2 For these
patients, test sensitivity can be improved by simultan-
eous measurement of methane.2 A related cause of
false-negative results in some individuals may be ‘full
colonic adaptation’ to lactose ingestion, in which
repeated intake of lactose selectively favours the
growth of colonic ﬂora that rapidly ferment lactose
without producing hydrogen.27,28 Currently, the genetic
test (in Caucasians) and the H2-breath test are widely
used in clinical practice. Studies in Caucasian popula-
tions without gastrointestinal comorbidity report a
high degree of agreement for diagnosis of lactose mal-
absorption between the H2-breath test, intestinal lac-
tase level, and genetic tests.14,23,24,29
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Assessment of lactose intolerance
The presence of lactose malabsorption is necessary but
is not suﬃcient to establish lactose intake as the cause
of patient symptoms. Lactose intolerance is deﬁned by
the occurrence of typical symptoms (i.e. nausea, bloat-
ing, diarrhoea, borborygmi, abdominal pain) during
the H2-breath test procedure. However, interpretation
of patient reports may be complicated by placebo
responses.
Self-reported food intolerance is reported by a large
proportion of the community in population-based stu-
dies, with frequency rates ranging from 9.5 to 25%30–32
and is even higher in patients with functional gastro-
intestinal diseases such as IBS.33,34 However, when sub-
jected to controlled and blinded testing, only 25–40%
of these patients react to the oﬀending food.30,32
Similarly, an open label challenge with 240ml of milk
induced symptoms in 59% of patients with lactose
malabsorption35 but had no signiﬁcant eﬀects in a
placebo-controlled challenge of subjects that self-
reported severe lactose intolerance (indeed nine out of
30 patients did not have lactose malabsorption on
breath testing).36 These ﬁndings demonstrate a high fre-
quency of placebo response to lactose in patients
referred for investigation of digestive symptoms. Such
a response might still impact on patient well being and
could be referred to as ‘functional lactose intolerance’
(Box 1). These studies also demonstrate that blinded
testing would increase the speciﬁcity of diagnosis and
guide more rational dietary management of lactose
intolerance. Double-blind placebo-controlled chal-
lenges for testing of food allergies has been criticized;37
however, these arguments do not apply to lactose
intolerance for which procedures can easily be standar-
dized and anaphylactic reactions will not occur.
Further, multiple-dose testing in a controlled and
blinded manner may have additional advantages.
Clear evidence of a dose–response eﬀect eliminates any
doubts about cause and eﬀect and this approach can also
Table 1. Summary of tests for lactose malabsorption and tolerance
H2-breath test Lactose tolerance test
Genetic test of –13910
C/T polymorphism
Lactase activity at
jejunal brush border
Test principle Increase of H2 in
respiratory air after
lactose challenge
Increase of blood sugar
after lactose
challenge
Genetic Polymorphism
13910 upstream of
lactase gene
Enzymatic activity of
lactase enzyme in
biopsy sample
Cut off >20 ppm within
3 hours
<1.1mmol/l within
3 hours
13910C/C indicates lac-
tase non-persistence
<17–20 IU/g
Availability Good Excellent Variable Rare
False positives
(malabsorption
incorrectly
diagnosed)
Rapid GI-transit, small-
intestinal bacterial
overgrowth
Rapid GI-transit,
impaired glucose
tolerance
Rare (<5%) in
Caucasians
Probably rare
False negatives
(malabsorption
wrongly excluded)
Non-H2-producers. Full
colonic adaptation.
Fluctuations in blood
sugar
All causes of secondary
lactose
malabsorption
Patchy enzyme
expression
Secondary causes Cannot be excluded,
kinetic of H2-
increase can be
suggestive
Cannot be excluded Cannot be excluded Can be excluded
(histopathology
obtained at same
procedure)
Assessment of
symptoms/lactose
tolerance
Possible Possible Not possible Not possible
Comment Method of choice for
assessment of lac-
tose malabsorption
and intolerance
Rarely performed due
to inferior sensitivity
and specificity
Definitive test for lac-
tase non-persistence
in Caucasians. Less
suitable in other
populations.
Reference standard for
detection of lactase
deficiency (primary
or secondary)
Not suitable in patients
with intestinal dis-
ease at risk of sec-
ondary lactase
deficiency.
Cost Low Lowest High Highest
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deﬁne individual lactose tolerance thresholds and guide
dietary management since patients often dramatically
underestimate the amount of lactose they could safely
ingest. Recently a double-blinded, randomized, three-
way cross-over comparison of lactose tolerance testing
at 10, 20, and 40 g lactose was performed in patients with
diarrhoea-predominant IBS (IBS-D) and controls in a
Chinese population with lactase deﬁciency.34 The pro-
portion of participants with an objective increase of at
least 20 ppm H2 increased progressively with lactose
dose and was similar in both groups (Table 2). In con-
trast, the proportion of IBS-D patients reporting typical
symptoms of lactose intolerance was signiﬁcantly higher
than for healthy subjects at every dose. Furthermore,
IBS-D patients reported multiple symptoms and more
severe symptoms compared to healthy subjects. These
ﬁndings conﬁrm that symptoms of lactose intolerance
are very rare at the low, 10 g lactose doses in healthy
subjects and are uncommon even in IBS patients with
lactase deﬁciency. Suchmultiple-dose testing with a dose
below normal symptom threshold (10 g), a dose reﬂect-
ing normal intake at a single meal (20 g), and a ‘positive
control’ (40 g) provides comprehensive information that
explains the causes of symptoms and guides clinical
management in a given patient.
In current practice, lactose tolerance testing is per-
formed as an open label procedure during the H2
breath test. The negative predictive value of these
tests is high and lack of symptoms after a 40–50 g lac-
tose challenge excludes lactose intolerance.38,39 In con-
trast, if symptoms develop, the possibility of a ‘placebo-
response’ should not be ignored especially in patients
without lactose malabsorption and those with func-
tional gastrointestinal disease or self-reported food
intolerance or allergies. Currently, placebo-controlled
or multiple-dose testing is not performed outside
research studies and would be diﬃcult to implement
in clinical practice. One solution to this practical issue
would be, after conﬁrming lactase deﬁciency in the
laboratory, to perform blinded testing at multiple
doses in the home environment. This approach could
facilitate widespread implementation of appropriate
dietary management rather than absolute exclusion of
lactose intake. A diagnostic algorithm for lactose mal-
absorption and intolerance is provided in Figure 2.
Treatment of lactose intolerance
Treatment of lactose intolerance should not be aimed at
reducing malabsorption but rather at improving digest-
ive symptoms. Reduction of lactose intake (Table 3)
rather than exclusion is recommended because, as
noted above, in blinded studies most patients with
self-reported lactose intolerance can ingest at least 12 g
lactose (equivalent to 250 ml milk) without experiencing
symptoms36,40,41 and taken with other foods, up to 18 g
lactose can often be tolerated.41 It should be emphasized
that the amount of lactose in tablets (<500mg) is very
unlikely to cause gastrointestinal complaints under any
circumstances,42 whereas symptoms after intake of
small amounts of dairy products should raise the suspi-
cion of a true food allergy to cow’s milk protein.
Observational studies report improvement of abdom-
inal complaints, with lactose restriction in up to 85%
of IBS patients with lactose malabsorption;43,44 how-
ever, in randomized controlled trials, no signiﬁcant
improvement has been found with dietary or enzyme-
replacement treatment.45,46 This lack of eﬃcacy in well-
designed trials may be because lactose is only one of
many poorly digestible, fermentable carbohydrates
and dietary ﬁbres in the diet.47 Therefore, even in
patients with lactase deﬁciency, lactose restriction will
rarely provide complete symptom relief. Consistent with
this hypothesis, a recent controlled trial of a diet low in
FODMAPs (Fermentable Oligo-, Di- and Mono-sac-
charides And Polyols) reported symptom improvement
in 86% of IBS patients, compared to 49% for a standard
dietary intervention.48
Lactase enzyme replacement is another option
although this changes the taste of the food when
mixed with the dairy products because glucose and gal-
actose produced by lactose digestion are sweeter than
the original sugar. A variety of preparations are avail-
able over the counter but may not be equally eﬀective.49
Another strategy involves probiotics that alter the
intestinal ﬂora and may have beneﬁcial eﬀects in IBS
patients that persist even after treatment.50 Finally,
although lactase expression is not upregulated by lac-
tose ingestion, tolerance may be induced by repeated
lactose dosing due to adaptation of the intestinal
ﬂora.41 Further studies are required to provide high-
quality evidence to support/compare the eﬃcacy of
these strategies.41
Table 2. Blinded multiple dose testing for lactose intolerance
10 g
lactose
20 g
lactose
40 g
lactose
Proportion of
individuals with
positive H2 breath
test >20 ppm
Controls 35 87 93
IBS-D patients 42 80 92
Proportion of
individuals with
typical symptoms
Controls 3 22 73
IBS-D patients 18* 47** 85*
Values are %. Results of a recent blinded, placebo controlled three-way
crossover trial.34
*p< 0.05, **p< 0.01 compared to healthy controls.
IBS, diarrhoea-predominant irritable bowel syndrome.
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In summary, restricting lactose intake is sensible
treatment for lactose intolerance but patients should
be reassured that absolute exclusion is unnecessary. If
patients are unwilling to reduce milk intake, then lac-
tase supplementation is appropriate. If typical abdom-
inal symptoms persist despite these measures, then a
trial of a diet low in FODMAPs may be more eﬀective.
Long-term effects of lactose restriction
Although restricting dietary lactose may improve
gastrointestinal complaints, long-term eﬀects of a diet
free of dairy products may be of concern.51 Dairy prod-
ucts are the major source of calcium in many individ-
uals (Table 3). Current guidelines suggest a daily
calcium intake of 1000mg per day for adults, 1300mg
Genetic test
Preferred in Caucasian patients
OR
OR
positive negative
No lactose malabsorption
no lactose
intolerance
yes no
reintroduce
milk products
consider alternative diagnosis
including IBS and SIBO
consider blinding testing
for lactose intolerance
start lactose
reduced diet
including
< 12g lactose/d
consider additional
testing if high
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Figure 2. Diagnostic algorithm for diagnosing lactose malabsorption and lactose intolerance
Diagnosis of lactose malabsorption is a pre-requisite for diagnosis of lactose intolerance (LI). Tests of malabsorption (genetic, biopsy)
should be followed by a test of intolerance before lactose restriction is recommended. Blinded testing at multiple doses in the home
setting may help guide rational dietary management; however, protocols still need to be established. LI, lactose intolerance; IBS, irritable
bowel syndrome; SIBO, small intestinal bacterial overgrowth.
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for adolescents, and 1200mg for people over 50 years.52
Drinking three cups of milk per day has been recom-
mended to obtain this amount.52 It has been shown that
adults and adolescents with a homozygous 13910*C
genotype or self-reported milk intolerance consume less
milk or lactose and less calcium than controls.51,53
There is also some evidence that a low intake of dairy
products is associated with a higher risk of fractures in
women, although much less so in men.51,54 Similarly,
the 13910*C genotype was a risk factor for osteopor-
osis in some studies51,55,56 but not in others.51,57 No
study has addressed the safety and eﬀectiveness of cal-
cium replacement for patients with lactose intolerance;
however, it seems reasonable to recommend increasing
calcium intake from other sources in patients that
restrict intake of dairy products and to have a low
threshold for calcium replacements in the presence of
other risk factors for osteoporosis.
Conclusions
Progress has been made in our understanding of lactose
malabsorption and intolerance. Sensitive and speciﬁc
tests for lactase deﬁciency are now available.
Diagnosis of lactose intolerance is less deﬁnitive as it
requires concurrent assessment of lactose digestion and
abdominal symptoms. Due to high rates of self-
reported intolerance of dairy products and the fact
that even patients with lactase deﬁciency can often tol-
erate up to 20 g lactose, such tests may be best per-
formed as a series of blinded procedures at multiple
doses. This approach provides information that can
guide rational dietary management; however, the prac-
tical implementation of such testing is still unresolved.
Once the optimal diagnostic method has been estab-
lished, studies will be needed to assess the long-term
outcome of dietary interventions.
Sources and selection criteria
We identiﬁed randomized controlled trials for diagnosis
and treatment of lactose malabsorption and intoler-
ance. This research had been done by an NIH evidence
report51 and others;18,41 however, high-quality, evi-
dence-based guidelines were not available. We identi-
ﬁed additional studies through Medline using search
terms ‘lactose malabsorption’, ‘lactose maldigestion’,
‘lactose intolerance’, ‘intolerance AND dairy OR
milk’, and also examined our own database for appro-
priate publications that tackle these issues.
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